Dividat Competitors

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

Kry is Europe’s largest digital healthcare provider, allowing patients to see a doctor, nurse, or psychologist through video consultations within minutes. We’ve delivered 11+ million patient appointments transforming access to high quality care at scale. Above all else, we’re driven by our vision of great healthcare for everyone. Headquartered in Stockholm and backed by some of Europe’s most renowned investors, our employees and 3000+ healthcare professionals are committed to improving the world’s health through innovation, one patient at a time. Through our products, we’re harnessing the power of technology to integrate, primary, urgent and secondary care within digital and physical care settings so patients connect to the right care, at the right time. We work with partners to tailor member journeys and with public health systems to deliver efficient care, at a lower cost. In Sweden and Norway you may know us as Kry. In the UK and France we operate under the name Livi. To learn more, visit www.kry.se / www.livi.co.uk / www.livi.fr / www.kry.no

Neuralink is a neurotechnology company building a generalized input/output platform for the brain. Our work has the potential to restore autonomy to those with unmet medical needs and fundamentally transform how humans interact with the world. Our core technology is an implantable brain-computer interface with ultra-thin, flexible electrode threads placed precisely by a surgical robot, enabling high-bandwidth, bidirectional interaction with neural signals. We’ve received multiple FDA Breakthrough Device designations and are conducting clinical trials around the world. Trial participants are exploring how our implant could enhance their daily lives — controlling digital devices like computers and smartphones, operating physical devices like robotic arms and wheelchairs, and translating thought directly into speech and text. Developing brain-computer interfaces is an interdisciplinary challenge, and we’re looking for exceptional talent across engineering, science, and operations. Explore opportunities to contribute to our mission at neuralink.com/careers.